Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 21Other hematologic neoplasm 17Lymphoid 16Gastrointestinal 15Thoracic 13Plasma cell 10Dermatologic 9Sarcoma 8Gynecologic 7Genitourinary 7CNS 7Head & Neck 4Classical hematology 4Myeloid 3Other neoplasm 2Other 1

Conditions

Obesity 410Neoplasms 151Mucositis 128Sexual Dysfunction, Physiological 105Breast Neoplasms 105Polycystic Ovary Syndrome 98Overweight 98Dyspnea 62Constipation 57Motor Activity 54Head and Neck Neoplasms 47Prostatic Neoplasms 42Weight Loss 39Diabetes Mellitus 36Pain 34Colorectal Neoplasms 33Endometrial Neoplasms 29Stomatitis 28Opioid-Induced Constipation 28Lung Neoplasms 28Depression 26Diabetes Mellitus, Type 2 24Cardiovascular Diseases 23Obesity, Morbid 22Multiple Endocrine Neoplasia Type 1 22Insulin Resistance 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Anxiety Disorders 21Hypertension 19Sexual Dysfunctions, Psychological 18

Interventions

Melphalan 1Fibroblast Growth Factor 7 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × Other × Clear all
NCT00482846 2014-04-15

Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma

Barbara Ann Karmanos Cancer Institute

Phase 1 Completed
38 enrolled
OtherPlasma cell

Multiple Myeloma, Mucositis, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡